These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
285 related articles for article (PubMed ID: 32633024)
1. Role of aldo-keto reductase family 1 member B1 (AKR1B1) in the cancer process and its therapeutic potential. Khayami R; Hashemi SR; Kerachian MA J Cell Mol Med; 2020 Aug; 24(16):8890-8902. PubMed ID: 32633024 [TBL] [Abstract][Full Text] [Related]
2. Aldo-keto reductase family 1 member B1 inhibitors: old drugs with new perspectives. Liu J; Wen G; Cao D Recent Pat Anticancer Drug Discov; 2009 Nov; 4(3):246-53. PubMed ID: 19522700 [TBL] [Abstract][Full Text] [Related]
3. Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members. O'connor T; Ireland LS; Harrison DJ; Hayes JD Biochem J; 1999 Oct; 343 Pt 2(Pt 2):487-504. PubMed ID: 10510318 [TBL] [Abstract][Full Text] [Related]
4. Repurposing of Strychnine as the Potential Inhibitors of Aldo-keto Reductase Family 1 Members B1 and B10: Computational Modeling and Pharmacokinetic Analysis. Sarfraz M; Aziz M; Afzal S; Channar PA; Alsfouk BA; Kandhro GA; Hassan S; Sultan A; Hamad A; Arafat M; Qaiser MN; Ahmed A; Siddique F; Ejaz SA Protein J; 2024 Apr; 43(2):207-224. PubMed ID: 37940790 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of an aldo-keto reductase gene signature with prognostic significance in colon cancer via activation of epithelial to mesenchymal transition and the p70S6K pathway. Demirkol Canlı S; Seza EG; Sheraj I; Gömçeli I; Turhan N; Carberry S; Prehn JHM; Güre AO; Banerjee S Carcinogenesis; 2020 Sep; 41(9):1219-1228. PubMed ID: 32628753 [TBL] [Abstract][Full Text] [Related]
6. Inhibitor selectivity between aldo-keto reductase superfamily members AKR1B10 and AKR1B1: role of Trp112 (Trp111). Zhang L; Zhang H; Zhao Y; Li Z; Chen S; Zhai J; Chen Y; Xie W; Wang Z; Li Q; Zheng X; Hu X FEBS Lett; 2013 Nov; 587(22):3681-6. PubMed ID: 24100137 [TBL] [Abstract][Full Text] [Related]
7. β2-AR regulates the expression of AKR1B1 in human pancreatic cancer cells and promotes their proliferation via the ERK1/2 pathway. Xiao MB; Jin DD; Jiao YJ; Ni WK; Liu JX; Qu LS; Lu CH; Ni RZ; Jiang F; Chen WC Mol Biol Rep; 2018 Dec; 45(6):1863-1871. PubMed ID: 30306507 [TBL] [Abstract][Full Text] [Related]
8. The AKR1B1 inhibitor epalrestat suppresses the progression of cervical cancer. Ji J; Xu MX; Qian TY; Zhu SZ; Jiang F; Liu ZX; Xu WS; Zhou J; Xiao MB Mol Biol Rep; 2020 Aug; 47(8):6091-6103. PubMed ID: 32761301 [TBL] [Abstract][Full Text] [Related]
9. The Expression and Clinical Significance of Aldo-Keto Reductase 1 Member B1 in Gastric Carcinoma. Li X; Yang J; Gu X; Xu J; Li H; Qian J; Chen L DNA Cell Biol; 2020 Jul; 39(7):1322-1327. PubMed ID: 32412859 [TBL] [Abstract][Full Text] [Related]
10. Aldo-Keto Reductase Family 1 Member B10 Inhibitors: Potential Drugs for Cancer Treatment. Huang L; He R; Luo W; Zhu YS; Li J; Tan T; Zhang X; Hu Z; Luo D Recent Pat Anticancer Drug Discov; 2016; 11(2):184-96. PubMed ID: 26844556 [TBL] [Abstract][Full Text] [Related]
11. Opposing roles of the aldo-keto reductases AKR1B1 and AKR1B10 in colorectal cancer. Taskoparan B; Seza EG; Demirkol S; Tuncer S; Stefek M; Gure AO; Banerjee S Cell Oncol (Dordr); 2017 Dec; 40(6):563-578. PubMed ID: 28929377 [TBL] [Abstract][Full Text] [Related]
12. AKR1B1 promotes basal-like breast cancer progression by a positive feedback loop that activates the EMT program. Wu X; Li X; Fu Q; Cao Q; Chen X; Wang M; Yu J; Long J; Yao J; Liu H; Wang D; Liao R; Dong C J Exp Med; 2017 Apr; 214(4):1065-1079. PubMed ID: 28270406 [TBL] [Abstract][Full Text] [Related]
13. Protective Effect of Aldo-keto Reductase 1B1 Against Neuronal Cell Damage Elicited by 4'-Fluoro-α-pyrrolidinononanophenone. Morikawa Y; Miyazono H; Kamase K; Suenami K; Sasajima Y; Sato K; Endo S; Monguchi Y; Takekoshi Y; Ikari A; Matsunaga T Neurotox Res; 2021 Aug; 39(4):1360-1371. PubMed ID: 34043181 [TBL] [Abstract][Full Text] [Related]
14. Overexpression and enhanced specific activity of aldoketo reductases (AKR1B1 & AKR1B10) in human breast cancers. Reddy KA; Kumar PU; Srinivasulu M; Triveni B; Sharada K; Ismail A; Reddy GB Breast; 2017 Feb; 31():137-143. PubMed ID: 27855345 [TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29. Ebert B; Kisiela M; Wsól V; Maser E Chem Biol Interact; 2011 May; 191(1-3):239-49. PubMed ID: 21215737 [TBL] [Abstract][Full Text] [Related]
16. AKR1B1 as a Prognostic Biomarker of High-Grade Serous Ovarian Cancer. Hojnik M; Šuster NK; Smrkolj Š; Sisinger D; Grazio SF; Verdenik I; Rižner TL Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159076 [TBL] [Abstract][Full Text] [Related]
17. AKR1B1 and AKR1B10 as Prognostic Biomarkers of Endometrioid Endometrial Carcinomas. Hojnik M; Frković Grazio S; Verdenik I; Rižner TL Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298614 [TBL] [Abstract][Full Text] [Related]
18. Molecular Interactions and Implications of Aldose Reductase Inhibition by PGA1 and Clinically Used Prostaglandins. Díez-Dacal B; Sánchez-Gómez FJ; Sánchez-Murcia PA; Milackova I; Zimmerman T; Ballekova J; García-Martín E; Agúndez JA; Gharbi S; Gago F; Stefek M; Pérez-Sala D Mol Pharmacol; 2016 Jan; 89(1):42-52. PubMed ID: 26487510 [TBL] [Abstract][Full Text] [Related]
19. Bioinformatics Analysis Reveals the Vital Role of AKR1B1 in Immune Infiltration and Clinical Outcomes of Gastric Cancer. Zhao Z; Hao Z; Zhang Z; Zhan X DNA Cell Biol; 2023 Jul; 42(7):372-389. PubMed ID: 37285280 [TBL] [Abstract][Full Text] [Related]
20. A Potential Prognostic Biomarker for Glioma: Aldo-Keto Reductase Family 1 Member B1. Zhao H; Dong X; Huang T; Li X Comput Intell Neurosci; 2022; 2022():9979200. PubMed ID: 35341178 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]